Dr. Luke J. Mountjoy, DO
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Des Moines University of Osteopathic Medicine and Health Sciences (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 256
Licensed in Colorado since 2019, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Des Moines University of Osteopathic Medicine and Health Sciences
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license 0062549 (first issued 2019; active) · AZ license 007210 -
Internal Medicine Physician
CO license DR0062549 (first issued 2019; active) · IA license R10122
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Poudre Valley Hospital Fort Collins, CO
- HCA Healthone Presbyterian St. Lukes Denver, CO
Medical groups
- Healthone Clinic Services - Oncology Hematology LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 256
- Services billed
- 23,768
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,040 | 20 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 800 | 12 |
| Insertion of needle into vein for collection of blood sample | 500 | 81 |
| Injection, magnesium sulfate, per 500 mg | 416 | 25 |
| Injection, ondansetron hydrochloride, per 1 mg | 288 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 221 | 77 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 98 | 35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | 47 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 64 | 38 |
| Administration of chemotherapy into vein, 1 hour or less | 48 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Denver, CO | 139 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Denver, CO | 97 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Denver, CO | 85 |
| Jakafi (ruxolitinib phosphate) | 81 |
| Prednisone Other prescribers in Denver, CO | 35 |
| Prevymis (letermovir) | 32 |
| Eliquis (apixaban) Other prescribers in Denver, CO | 29 |
| Lenalidomide | 27 |
| Hydrocortisone Other prescribers in Denver, CO | 26 |
| Dexamethasone Other prescribers in Denver, CO | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 16 payments worth $348 in total to this clinician.
| AbbVie Inc. | $237 |
|---|---|
| Astellas Pharma US Inc | $40.61 |
| Iovance Biotherapeutics, Inc. | $24.93 |
| Ipsen Biopharmaceuticals, Inc | $23.80 |
| Celgene Corporation | $22.24 |
| Food and Beverage | $348 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $421,553 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC - AUTO1-AL1
Autolus Inc - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation - A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy A - Relapsed/Refractory Waldenstrom Macrogl…
Kite Pharma, Inc. - Phase 1 EIH CD19 4 1BBL
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.